{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:49:15Z","timestamp":1792439355294,"version":"4.5.0"},"reference-count":16,"publisher":"Korean Association for the Study of Intestinal Diseases","issue":"4","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["irjournal.org"],"crossmark-restriction":true},"short-container-title":["Intest Res"],"published-print":{"date-parts":[[2025,10,31]]},"abstract":"<jats:p>Background\/Aims: Inflammatory bowel disease (IBD) is characterised by chronic inflammation of the gastrointestinal tract, and encompasses both ulcerative colitis (UC) and Crohn\u2019s disease (CD). Refractory disease is common, a combination of advanced drug therapies may be required to obtain maximal efficacy. We describe the use of upadacitinib therapy in combination with vedolizumab therapy for the management of refractory UC and CD. Methods: In this retrospective observational study, patients who received upadacitinib in combination with vedolizumab were identified at a tertiary IBD center between November 2022 and March 2024. Patients were followed for 6 months with clinical, biochemical, endoscopic and intestinal ultrasound outcomes. Results: Sixteen patients (7 with UC, 9 with CD) were identified. Median age was 44 years (range, 25\u201358 years), 11 (69%) were male, and median number of prior biologic exposures was 3 (range, 2\u20135). Twelve patients (75%) achieved clinical response, clinical remission, biochemical remission, corticosteroid-free clinical remission, and transmural remission by intestinal ultrasound. Eleven patients (69%) achieved endoscopic remission, with 4 (25%) achieving histological remission. Adverse events were seen in 8 patients (50%), but the majority were mild and did not require interruption of therapy. Conclusions: Upadacitinib in combination with vedolizumab may have a role in refractory UC and CD patients who have previously failed to respond to standard therapy, with a favorable safety profile. Prospective studies are required to determine the safety and efficacy of this combination in larger cohorts before routine use can be recommended.<\/jats:p>","DOI":"10.5217\/ir.2024.00174","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T04:13:21Z","timestamp":1749442401000},"page":"475-482","update-policy":"https:\/\/doi.org\/10.5217\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn\u2019s disease"],"prefix":"10.5217","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6648-658X","authenticated-orcid":true,"given":"Robert","family":"Gilmore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8681-2274","authenticated-orcid":true,"given":"Amrutha","family":"Murali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0337-8463","authenticated-orcid":true,"given":"Amirah","family":"Etchegaray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4565-1996","authenticated-orcid":true,"given":"Ei","family":"Swe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1458-8015","authenticated-orcid":true,"given":"Yoon-Kyo","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5256-7672","authenticated-orcid":true,"given":"Jakob","family":"Begun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3168","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16445"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00427-7"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.31.1.100"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)00581-5"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2212728"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i23.2457"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1215734"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1215739"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v28.i47.6743"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/meg.0000000000002690"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12436"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-023-08182-y"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2024.00127"},{"key":"ref15","first-page":"S1169","volume-title":"Novel use of cyclosporine induction therapy as a bridge to tofacitinib in severe ulcerative colitis: 2050","author":"Weisshof","year":"2018"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otab030"}],"container-title":["Intestinal Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/irjournal.org\/upload\/pdf\/ir-2024-00174.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/irjournal.org\/journal\/view.php?doi=10.5217\/ir.2024.00174","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/irjournal.org\/upload\/pdf\/ir-2024-00174.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T04:55:26Z","timestamp":1762318526000},"score":1,"resource":{"primary":{"URL":"http:\/\/irjournal.org\/journal\/view.php?doi=10.5217\/ir.2024.00174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"URL":"https:\/\/doi.org\/10.5217\/ir.2024.00174","relation":{},"ISSN":["1598-9100","2288-1956"],"issn-type":[{"value":"1598-9100","type":"print"},{"value":"2288-1956","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"2024-10-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-09","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-31","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}